COVID-19: Drugs in Development

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name

Drug

Current Stage

Next Milestone

Collaboration

Last Updated

Immunic, Inc
(IMUX)

IMU-838 for COVID-19.

Phase 2b study in combination with Tamiflu in adult patients with moderate-to-severe COVID-19 (IONIC)

Top-line data expected later in 2020

University Hospitals Coventry and Warwickshire NHS Trust

09/28/2020

Atreca Inc.
(BCEL)

Antibody Treatment for COVID-19

Research

Begin clinical testing in the first half of 2021

BeiGene Ltd. (BGNE) and IGM Biosciences Inc. (IGMS)

09/25/2020

Pfizer Inc.
(PFE)

BNT162 Vaccine program

BNT162 program includes 4 vaccine candidates; BNT162b2 has been advanced into phase 2/3 global trial

Regulatory review for BNT162b2 to be sought as early as October 2020

BioNTech SE

09/25/2020

PDS Biotechnology Corp
(PDSB)

PDS0204 COVID-19 vaccine

Preclinical studies

Farmacore, Brazilian Ministry of Science, Technology, Innovation and Communication (MCTIC).

09/25/2020

Akari Therapeutics Plc
(AKTX)

Nomacopan for COVID-19 pneumonia patients

Phase I/II study in the U.K. to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19 (AGILE)

09/25/2020

Denali Therapeutics Inc.
(DNLI)

DNL758

Phase Ib study of DNL758 in hospitalized adult patients with severe COVID-19 lung disease

Sanofi

09/25/2020

CureVac N.V.
(CVAC)

mRNA coronavirus vaccine

Phase I study in Germany and Belgium

Initial results from phase I study expected early in the fourth quarter. Based on the results of the phase I trial, the COVID-19 vaccine candidate will advance into a phase IIb/III trial in Q4, 2020

CEPI, Bill & Melinda Gates Foundation and Defense Advanced Research Projects Agency (DARPA)

09/02/2020

Sanofi
( SNYNF, SNY)

Kevzara (Repurposed drug)

Phase 3 trial investigating intravenously administered Kevzara at a dose of 200 mg or 400 mg in severely or critically patients hospitalized with COVID-19 did not meet its primary endpoint and key secondary endpoint

Regeneron Pharmaceuticals, Inc. (REGN)

09/01/2020

Previous Records

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Biotech Stocks Facing FDA Decision In October 2020

New Drugs Approved In August

Biotech Stocks Facing FDA Decision In September

Editors Pick

Elon Musk Mulls IPO For SpaceX's Starlink 'several Years In Future'

Elon Musk, the founder and CEO of Space Exploration Technologies, or SpaceX, said the aerospace company is planning to list its space internet venture, Starlink, after many years when revenue growth is smooth and predictable. In a tweet, Musk said, "We will probably IPO Starlink, but only several years in the future when revenue growth is smooth & predictable. Public market does *not* like erratic

Tuesday Is National Coffee Day

It's again that day of the year when coffee lovers celebrate their passion for the caffeinated beverage. It is National Coffee Day today in the U.S. when major food and beverage outlets nationwide promote the coffee culture with deals for coffee fans. In the U.S., major coffee outlets such as Starbucks, Dunkin' Donuts, Wawa, Krispy Kreme, Wendy's and Panera Bread give away free cups of coffee.

GM To Repay $28 Mln Tax Credits To Ohio After Closing Lordstown Plant

The state of Ohio ordered General Motors to repay $28 million in tax credits after closing the Lordstown plant, which was in agreement to be operated until 2040. The Ohio Tax Credit Authority said the closure violated the terms of two economic development agreements signed by the company. In separate development, GM announced it is investing $71 million in two other Ohio manufacturing facilities.

Latest Updates on COVID-19